The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.
Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial
Abstract
Randomized trials have indicated that well-managed anticoagulation with warfarin could prevent more than half of the strokes related to atrial fibrillation. However, many patients with atrial fibrillation who are eligible for this therapy either do not receive it or are not maintained within an optimal prothrombin time-international normalized ratio (INR) range. We sought to determine whether an anticoagulation service within a managed care organization would be a feasible alternative for providing anticoagulation care. We performed a multi-site randomized trial in six large managed care organizations in the United States. Subjects were aged 65 years or older and had nonvalvular atrial fibrillation. At each site, physician practices were divided into two geographically defined practice clusters; each site was randomly assigned to have one intervention and one control cluster. The intervention cluster received an anticoagulation service that satisfied specifications for high-quality anticoagulation care and was coordinated through the managed care organization. Control clusters continued with their usual provider-based care. We measured the proportion of time that warfarin-treated patients in each of the clusters (intervention and control) were in the target range for the INR at baseline, and again during a follow-up period. Five of the six selected sites succeeded at developing an anticoagulation service. Patients in the intervention and control clusters had similar demographic characteristics, contraindications to warfarin, and risk factors for stroke. Among patients (n = 144 in the intervention clusters; n = 118 in the control clusters) for whom data were available during the baseline and follow-up periods, the changes in percentages of time in the target range were similar for those in the intervention clusters (baseline: 47.7%; follow-up: 55.6%) and in the control clusters (baseline: 49.1%; follow-up: 52.3%; intervention effect: 5%; 95% confidence interval: -5% to 14%; P = 0.32). Although it was feasible in a managed care organization to implement anticoagulation services that were tailored to local circumstances, provision of this service did not improve anticoagulation care compared with usual care. The effect of the anticoagulation service was limited by the utilization of the service, the degree to which the referring physician supports strict adherence to recommended target ranges for the INR, and the ability of the anticoagulation service to identify and to respond to out-of-range values promptly.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other bias Unclear risk Contamination may have been possible, since geographically related practices were randomised to intervention and control groups. Patient characteristics were similar in both groups”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
In the citing paper
“Selective reporting (reporting bias) Low risk Appropriate outcomes reported”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
In the citing paper
“Risk of bias overall High risk 5 unclear risk criteria, including allocation concealment”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
In the citing paper
“Random sequence generation (selection bias) Low risk A computer random number function was used”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
In the citing paper
“Allocation concealment (selection bias) Unclear risk Process not reported”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
In the citing paper
“Blinding of outcome assessment (detection bias) All outcomes Unclear risk Whether or not the data abstractors were blinded is not reported”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
In the citing paper
“Baseline characteristics Unclear risk There were no differences in patient characteristics between study groups. No data on clinicians”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
In the citing paper
“Contamination Low risk Groups of geographically related practices were randomised”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
In the citing paper
“Baseline outcomes Low risk No differences at baseline”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
In the citing paper
“Incomplete outcome data (attrition bias) All outcomes High risk 30% attrition is reported”
From Tailored interventions to address determinants of practice (2015) · cites this paper as Matchar 2002
Citations
Cites
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,421
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.13.1449 · Cited by 2,643
Statistical Power Analysis for the Behavioral Sciences
(1977) · doi:10.1016/c2013-0-10517-x · Cited by 2,457
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,877
Petersen, P., GODTFREDSEN, J., Boysen, G., Andersen, E. D., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,814
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H. I., Ansell, J., & Deykin, D. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,813
Stroke Prevention in Atrial Fibrillation Study. Final results.
Prevention, S., & Atrial Fibrillation Investigators (1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696
Research works printed but not linked: 1
- Samsa, 1998, A seven-step model for practice improvement research, New Med, 2, 139
Cited by
Sorted by citations
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E. M., Jacobson, A. K., Crowther, M. A., & Palareti, G. (2008) · CHEST Journal · doi:10.1378/chest.08-0670 · Cited by 2,135
“The study by Matchar et al 287 also failed to show a significant improvement in TTR between the two models of care, although the AMS performed modestly better than UC.”
ResultIncidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting
Gurwitz, J. H., Field, T. S., Harrold, L. R., Rothschild, J. M., DeBellis, K. R., Seger, A. C., Cadoret, C. A., Fish, L. S., Garber, L., Kelleher, M., et al. (2003) · JAMA · doi:10.1001/jama.289.9.1107 · Cited by 1,666
“While more widespread use of specialized clinics for anticoagulation therapy to provide coordinated care has been promoted to improve the effectiveness and safety of warfarin in elderly patients,(30) to date the benefits of this approach relative to usual care have not been established.(31) While most antibiotic-assoc…”
BackgroundThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H. I., Jacobson, A. K., & Hylek, E. M. (2004) · CHEST Journal · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,530
Ageno, W., Gallus, A. S., Wittkowsky, A. K., Crowther, M. A., Hylek, E. M., & Palareti, G. (2012) · CHEST Journal · doi:10.1378/chest.11-2292 · Cited by 1,583
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A. M., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M. A., & Guyatt, G. H. (2012) · CHEST Journal · doi:10.1378/chest.11-2295 · Cited by 1,292
The Clinical Profile and Pathophysiology of Atrial Fibrillation
Andrade, J. G., Khairy, P., Dobrev, D., & Nattel, S. (2014) · Circulation Research · doi:10.1161/circresaha.114.303211 · Cited by 1,232
“spite strong evidence of efficacy, OAC use is limited by nonprescription (≈50% patients do not receive OAC, despite an appropriate indication),(159,160) nonadherence (30% 1-year discontinuation for warfarin),(161) and subtherapeutic dosing (≈25%–38% of warfarin-treated patients).(162,163) Suboptimal”
BackgroundBaker, R., Camosso-Stefinovic, J., Gillies, C., Shaw, E. J., Cheater, F., Flottorp, S., & Robertson, N. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005470.pub2 · Cited by 1,003
Tailored interventions to address determinants of practice
Baker, R., Camosso-Stefinovic, J., Gillies, C., Shaw, E. J., Cheater, F., Flottorp, S., Robertson, N., Wensing, M., Fiander, M., Eccles, M. P., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005470.pub3 · Cited by 711
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G. E., Beyth, R. J., Kearon, C., & Schulman, S. (2004) · CHEST Journal · doi:10.1378/chest.126.3_suppl.287s · Cited by 519
Wan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., Glasziou, P., Bankhead, C., & Xu, Y. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.796185 · Cited by 514
Witt, D. M., Sadler, M. A., Shanahan, R. L., Mazzoli, G., & Tillman, D. J. (2005) · CHEST Journal · doi:10.1378/chest.127.5.1515 · Cited by 348
Guyatt, G. H., Akl, E. A., Crowther, M. A., Gutterman, D. D., & nemann, H. J. S. (2013) · Cited by 288
Tailoring quality improvement interventions to identified barriers: a multiple case analysis
Bosch, M., Van Der Weijden, T., Wensing, M., & Grol, R. (2007) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2006.00660.x · Cited by 272
Effect of home testing of international normalized ratio on clinical events
Matchar, D. B., Jacobson, A., Dolor, R., Edson, R., Uyeda, L., Phibbs, C. S., Vertrees, J. E., Shih, M.-C., Holodniy, M., & Lavori, P. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002617 · Cited by 266
“Nonstroke thrombotic event§§ 34 (2) 41 (3) 0.”
Self-citationWarfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation
Reynolds, M. W., Fahrbach, K. R., Hauch, O., Wygant, G. D., Estok, R. P., Cella, C., & Nalysnyk, L. (2004) · CHEST Journal · doi:10.1378/chest.126.6.1938 · Cited by 262
Gurwitz, J. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.18.1957 · Cited by 190
Young, M. P., Manning, H. L., Wilson, D. L., Mette, S. A., Riker, R. R., Leiter, J. C., Liu, S. K., Bates, J. H. T., & Parsons, P. E. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000127784.54727.56 · Cited by 189
“(19) found that the tidal volume decreased only modestly after publication of the ARDSNet trial (the reduction they found was even smaller than the reduction we identified); the trend toward smaller tidal volumes actually started before the ARDSNet results were published (we saw no evidence of this in our own study: T…”
ResultCheater, F., Baker, R., Gillies, C., Hearnshaw, H., Flottorp, S. A., Robertson, N., Shaw, E. J., & Oxman, A. D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005470 · Cited by 182
Health literacy and anticoagulation-related outcomes among patients taking warfarin
Fang, M. C., Machtinger, E. L., Wang, F. M., & Schillinger, D. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00537.x · Cited by 175
Sullivan, P. W., Arant, T., Ellis, S. L., & Ulrich, H. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624100-00009 · Cited by 147
Fang, M. C. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6101 · Cited by 144
Verheugt, F. W. A., & Granger, C. B. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60245-8 · Cited by 137
Klok, F. A., Kooiman, J., Huisman, M. V., Konstantinides, S., & Lankeit, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00040714 · Cited by 113
Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation
Patrick, A. R., Avorn, J., & Choudhry, N. K. (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.808592 · Cited by 108
Mearns, E. S., White, C. M., Kohn, C. G., Hawthorne, J., Song, J.-S., Meng, J., Schein, J. R., Raut, M. K., & Coleman, C. I. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-14 · Cited by 106
“Matchar (control) 2002 [62] RCT 317 76 NR N.”
MethodMani, H., & Lindhoff‐Last, E. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s45644 · Cited by 101
The Safety of Warfarin Therapy in the Nursing Home Setting
Gurwitz, J. H., Field, T. S., Radford, M. J., Harrold, L. R., Becker, R. C., Reed, G. W., DeBellis, K. R., Moldoff, J., & Verzier, N. R. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.07.045 · Cited by 95
Boulanger, L., Kim, J. S., Friedman, M., Hauch, O., Foster, T., & Menzin, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00790.x · Cited by 94
Personalisation of warfarin therapy using thermal ink-jet printing
Vuddanda, P. R., Alomari, M., Dodoo, C. C., Trenfield, S. J., Velaga, S. P., Basit, A. W., & Gaisford, S. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.02.002 · Cited by 91
Atrial Fibrillation in the Elderly
Fang, M. C., Chen, J., & Rich, M. W. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.01.026 · Cited by 91
Major Bleeding Complications in a Specialized Anticoagulation Service
Fanikos, J. R., Grasso-Correnti, N., Shah, R. V., Kucher, N., & Goldhaber, S. Z. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.03.104 · Cited by 79
Menzin, J., Boulanger, L., Hauch, O., Friedman, M., Marple, C. B., Wygant, G. D., Hurley, J. S., Pezzella, S. M., & Kaatz, S. S. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e169 · Cited by 77
Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs
Wittkowsky, A. K., Boccuzzi, S. J., Wogen, J., Wygant, G. D., Patel, P., & Hauch, O. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.17.1668.52338 · Cited by 75
“The average proportion of time within the optimal range (time in range) is approximately 50% with routine monitoring and dosing adjustment protocols.(3) The risk of thromboembolic events”
BackgroundA Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity
Kim, M., Huang, S. M., Meyer, U., Rahman, A., & Lesko, L. J. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008328098 · Cited by 73
“One study showed that INR values were below and above therapeutic values for 31% and 14% of the time, respectively.(20) Clearly, approaches to optimal anticoagulation using conventional INR monitoring in both clinics and tertiary and primary care settings can be improved.”
BackgroundNovel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Schirmer, S. H., Baumhäkel, M., Neuberger, H., Hohnloser, S. H., Gelder, I. C. V., Lip, G. Y. H., & Böhm, M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.017 · Cited by 70
Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism
Klok, F. A., Niemann, C., Dellas, C., Hasenfuss, G. P., Konstantinides, S., & Lankeit, M. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1239-x · Cited by 70
“shown to reduce the number of bleedings as well [24, 25].”
BackgroundLalonde, L., Martineau, J., Blais, N., Montigny, M., Ginsberg, J., Fournier, M., Berbiche, D., Vanier, M., Blais, L., Perreault, S., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.02.009 · Cited by 67
Nichol, M. B., Knight, T. K., Dow, T., Wygant, G. D., Borok, G. M., Hauch, O., & O’Connor, R. D. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k157 · Cited by 59
The impact of pharmacist-managed oral anticoagulation therapy in older veterans
Poon, I. O., Lal, L. S., Brown, E. N., & Braun, U. K. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00792.x · Cited by 57
“To further investigate the effect of pharmacist-monitored anticoagulation outcomes, we reviewed the number of INR values £1Æ5, 4–9, >9 and calculated mean elapsed time between INR values £1Æ5, between 4 and 9, and >9 and the next INR value in days to assess the timeliness of response to non-therapeutic INR values (19,…”
MethodIndividualizing Warfarin Therapy
Reynolds, K. K., Valdes, R., Ramey-Hartung, B., & Linder, M. W. (2007) · Personalized Medicine · doi:10.2217/17410541.4.1.11 · Cited by 57
Randomized Trial of a Warfarin Communication Protocol for Nursing Homes: an SBAR-based Approach
Field, T. S., Tjia, J., Mazor, K. M., Donovan, J. L., Kanaan, A. O., Harrold, L. R., Reed, G. W., Doherty, P., Spenard, A., & Gurwitz, J. H. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.09.017 · Cited by 57
Darkow, T., Vanderplas, A. M., Lew, K. H., Kim, J., & Hauch, O. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x61956 · Cited by 57
Harrison, J., Shaw, J., & Harrison, J. (2014) · International Journal of Pharmacy Practice · doi:10.1111/ijpp.12148 · Cited by 55
Ogawa, S., Koretsune, Y., Yasaka, M., Aizawa, Y., Atarashi, H., Inoue, H., Kamakura, S., Kumagai, K., Mitamura, H., Okumura, K., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0304 · Cited by 55
Verhovsek, M. M., Motlagh, B., Crowther, M. A., Kennedy, C. C., Dolovich, L. R., Campbell, G., Wang, L., & Παπαϊωάννου, Α. (2008) · BMC Geriatrics · doi:10.1186/1471-2318-8-13 · Cited by 51
“0 for these common indications [6-8], maintenance of therapeutic INR in the community is generally poor [9-11].”
BackgroundMeasuring Quality of Oral Anticoagulation Care: Extending Quality Measurement to a New Field
Rose, A. J., Berlowitz, D. R., Frayne, S. M., & Hylek, E. M. (2009) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/s1553-7250(09)35019-9 · Cited by 51
The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation
Ezekowitz, M. D., & Falk, R. H. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.904 · Cited by 49
Monitoring anticoagulation in atrial fibrillation
Sarawate, C. A., Sikirica, M. V., Willey, V. J., Bullano, M. F., & Hauch, O. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-4968-z · Cited by 42
“Further, even in studies with more general clinical settings, and a population more similar to this one in terms of age and stroke risk factors, anticoagulation services may not be totally effective [28].”
BackgroundResultZhao, S., Zhao, H., Wang, X., Gao, C., Qin, Y., Cai, H., Chen, B., & Cao, J. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s120962 · Cited by 40
The quality of oral anticoagulation in general practice in patients with atrial fibrillation
Mueller, S., Pfannkuche, M., BREITHARDT, G. E., Bauersachs, R. M., Maywald, U., Kohlmann, T., & Wilke, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.12.013 · Cited by 35
“The data generated by the questionnaires addressed to the patients were used to calculate the following five scores: (1) HrQoL (EQ5-D score [25] and SF-36 sum scales [26]); (2) EHRA symptoms (severity from 0 to 3 multiplied with frequency from 1 to 3); (3) a non-adherence score [36] with a scale from 10 to 40 (higher…”
MethodThe Future of Anticoagulation Clinics
Macik, B. G. (2003) · Journal of Thrombosis and Thrombolysis · doi:10.1023/b:thro.0000014594.52685.33 · Cited by 32
Matchar, D. B., Jacobson, A. K., Edson, R., Lavori, P. W., Ansell, J., Ezekowitz, M. D., Rickles, F. R., Fiore, L., Boardman, K., Phibbs, C. S., et al. (2005) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-005-1452-0 · Cited by 32
“Despite the compelling evidence supporting the value of AC and the importance of high quality AC, warfarin remains underused and, for those receiving treatment, dosing is often suboptimal [2].”
BackgroundMethodInfluentialSelf-citationRole of the anticoagulant monitoring service in 2018: beyond warfarin
Clark, N. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.348 · Cited by 31
Zhu, Z., Li, C., Shen, J., Wu, K., Li, Y., Liu, K., Zhang, F., Zhang, Z., Li, Y., Han, J., et al. (2021) · Journal of Medical Internet Research · doi:10.2196/29529 · Cited by 29
“The conventional way to manage anticoagulation is face to face [12], but the quality of this approach depends highly on the patients’ compliance, resulting in difficulty in management and increased risk of adverse events [13,14].”
BackgroundDrug therapy in the elderly: Improving quality and access
Simon, S. R., & Gurwitz, J. H. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00011-0 · Cited by 29
“promise for improving the quality of anticoagulation care, it is important to note that a recent randomized, controlled trial failed to show that these specialized clinics improved the processes and outcomes of care for patients requiring anticoagulation.(67) Conversely, randomized, controlled trials have demonstrated…”
BackgroundPatterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices
Ewen, E. F., Simon, 。., Weintraub, Kolm, P., Zhang, Z., & Liu, X. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s34280 · Cited by 27
Tendera, M., Syzdół, M., & Parma, Z. (2012) · Cardiology Journal · doi:10.5603/cj.2012.0002 · Cited by 25
“Data from clinical trials show that patients with AF achieve the therapeutic INR range only during 60% of treatment time [8].”
MethodMatchar, D. B., Love, S. R., Jacobson, A. K., Edson, R., Uyeda, L., Phibbs, C. S., & Dolor, R. J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1128-8 · Cited by 22
“HQACM was defined as care that met the following criteria based on the deliberations of an expert panel [18]: a designated, trained staff responsible for patients’ visits and follow-up; the use of a standard, local procedure at each site for AC management; and the performance of regular INR testing approximately once…”
MethodSelf-citationSamsa, G. P., Matchar, D. B., Phillips, D. L., & McGrann, J. (2002) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1023276710895 · Cited by 22
“For UC and ACS, the distribution of time in each INR category was obtained from a randomized trial comparing anticoagulation services to usual care [3].”
MethodSelf-citationAt-Home Versus In-Clinic INR Monitoring: A Cost–Utility Analysis from The Home INR Study (THINRS)
Phibbs, C. S., Love, S. R., Jacobson, A. K., Edson, R., Su, P., Uyeda, L., & Matchar, D. B. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3700-8 · Cited by 22
Self-citationJACKSON, K. P., Gersh, B. J., Stockbridge, N., Fleming, T. R., Temple, R., Califf, R. M., Connolly, S. J., Wallentin, L. C., & Granger, C. B. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.01.023 · Cited by 21
“0 approximately 50% of the time.(23,24) Importantly, nearly two thirds of patients with AF who sustain an ischemic stroke while taking warfarin are below target range.”
BackgroundCeresetto, J. M. (2016) · Clinics · doi:10.6061/clinics/2016(01)07 · Cited by 22
“Real-world TTR levels are likely to be at least 10-20% lower (59).”
BackgroundLiang, J., Lao, C., Tian, L. H., Yang, Y., Wu, H.-M., Tong, H. H. Y., & Chan, A. (2019) · International Journal of Pharmacy Practice · doi:10.1111/ijpp.12584 · Cited by 20
“Previous literature reported that patients spent approximately 50% of TTR if their warfarin therapy were managed solely by physicians.([25,30,31]) The PEFS was estimated to enhance the TTR by about 10%.”
BackgroundBontempo, L. J., & Goralnick, E. (2011) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2011.08.008 · Cited by 20
Bleeding risks associated with vitamin K antagonists
Linkins, L. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.02.004 · Cited by 24
Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER.
Brennan, J. M., Alexander, K. P., Wallace, A., Hodges, A. B., Laschinger, J. C., Jones, K. W., O’Brien, S. M., Webb, L. E., Dokholyan, R. S., & Peterson, E. D. (2012) · PubMed · Cited by 19
Novel anticoagulants in atrial fibrillation stroke prevention
Norgard, N. B., DiNicolantonio, J. J., Topping, T. J., & Wee, B. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312438934 · Cited by 19
“Maintaining a therapeutic range has proven difficult as a significant number of patients’ INRs (international normalized ratios) deviate from target range resulting in an increased risk for either thromboembolism or hemorrhage [Matchar et al. 2002; Connolly et al. 2006; Gladstone et al. 2009].”
BackgroundDirect thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease
Morales‐Vidal, S., Schneck, M. J., Flaster, M. S., & Biller, J. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.185 · Cited by 16
Bringing the Benefits of Anticoagulation Management Services to the Community
Bungard, T. J., Archer, S. L., Hamilton, P. G., Ritchie, B. C., Tymchak, W. J., & Tsuyuki, R. T. (2006) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/171516350613900207 · Cited by 16
Changes in surrogate outcomes can be translated into clinical outcomes using a Monte Carlo model
van Walraven, C., Oake, N., Coyle, D., Taljaard, M., & Forster, A. J. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.01.015 · Cited by 15
Liu, S., Singer, A. G., McAlister, F. A., Peeler, W., Heran, B. S., Drummond, N., Manca, D. P., Allan, G. M., Korownyk, C. S., Kolber, M. R., et al. (2019) · PubMed Central · Cited by 13
Louis, K. M., Martineau, J., Rodrigues, I., Fournier, M., Berbiche, D., Blais, N., Ginsberg, J., Blais, L., Montigny, M., Perreault, S., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2009.11.015 · Cited by 13
Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France
Ruivard, M., Berger, C., Achaibi, A., Campagne, C., & Philippe, P. (2003) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2003.21230.x · Cited by 13
Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
Gabilondo, M., Loza, J. Á., Pereda, Á., Caballero, O., Zamora, N., Gorostiza, A., & Mar, J. (2021) · Hematology · doi:10.1080/16078454.2021.1892329 · Cited by 12
“indicates that the quality of anticoagulation with VKAs is related to the intensity of monitoring [23,24].”
BackgroundKing, S. R., King, E., Kuhl, D. A., & Peyton, L. (2020) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2020.04.026 · Cited by 12
Simmons, B. J., Jenner, K. M., Delate, T., Clark, N. P., Kurz, D., & Witt, D. M. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1139 · Cited by 12
Anticoagulation for atrial fibrillation
Fang, M. C., & Singer, D. E. (2004) · Cardiology Clinics · doi:10.1016/s0733-8651(03)00115-2 · Cited by 12
Willems, R., & Exner, D. V. (2004) · Journal of Interventional Cardiac Electrophysiology · doi:10.1023/b:jice.0000011340.74632.ac · Cited by 11
“It is clear that in order for such dedicated anticoagulation clinics to be successful there needs to be a commitment from payers and geographic stability within the population [45].”
BackgroundClinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients
Jones, K. L., Barnett, C. M., Gauthier, M., Boster, B. L., Espirito, J. L., & Michaud, L. B. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155210397775 · Cited by 11
“4% in the UC group.(18,19) Recurrent VTEs in our patient population are within the ranges of non-oncology patients that received AMS and UC, but lower than cancer patients receiving warfarin.”
MethodResultEggebrecht, L., Ludolph, P., Göbel, S., Panova‐Noeva, M., Arnold, N., Nagler, M., Bickel, C., Lauterbach, M., Hardt, R., Cate, H. T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82076-9 · Cited by 10
Does treatment guided by vitamin K in the diet alter the quality of life of anticoagulated patients?
de Assis, M. C. S., Cruz, L. N., Zuchinali, P., Rohde, L. E. P., & Rabelo, E. R. (2012) · PubMed · doi:10.3305/nh.2012.27.4.5847 · Cited by 9
Warfarin versus aspirin for stroke prevention (BAFTA)
Mihas, C. C., Alevizos, A., Arapaki, A., & Mariolis, A. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61679-1 · Cited by 9
Experiencia de una clínica de anticoagulación
Laverde, L. P., Gómez, S. E., Montenegro, A. C., Lineros, A., Wills, B., & Buitrago, A. F. (2015) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2015.04.008 · Cited by 8
Keller, K., Göbel, S., ten Cate, V., Panova‐Noeva, M., Eggebrecht, L., Nagler, M., Coldewey, M., Foebel, M., Bickel, C., Lauterbach, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103281 · Cited by 8
“By contrast, other studies did not report similarly high percentages of TTR, reporting median TTR values below 70% [21,22,32].”
ResultGrogan, A., Coughlan, M., Prizeman, G., O'Connell, N. M., O’Mahony, N., Quinn, K., & McKee, G. (2017) · Journal of Clinical Nursing · doi:10.1111/jocn.13767 · Cited by 8
Miller, P. S. J., Drummond, M., Langkilde, L. K., McMurray, J. J. V., & Ögren, M. (2005) · European Heart Journal Supplements · doi:10.1093/eurheartj/sui019 · Cited by 7
A Validated LC-MS/MS Method for the Estimation of Apixaban in Human Plasma
Baig, M. L. A., & Ali, S. A. (2017) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2017.70406 · Cited by 7
“: +919960883737 2011; Mueck et al., 2013; Matchar et al., 2002; Gadisseur et al., 2004; Shenker et al., 2012).”
Warfarin management after discharge from hospital: a qualitative analysis
Chalmers, L., van Tienen, E., Peterson, G. M., Bereznicki, L., Jackson, S., Bajorek, B. V., Mullan, J., & DeBoos, I. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01308.x · Cited by 7
Implications for Nursing Care of Patients With Atrial Fibrillation
Kellen, J. C. (2004) · The Journal of Cardiovascular Nursing · doi:10.1097/00005082-200403000-00007 · Cited by 7
Improving Adherence to Treatment Guidelines
Gándara, E., Moniz, T. T., Dolan, M. L., Melia, C., Dudley, J. C., Smith, A. J., & Kachalia, A. B. (2009) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0b013e3181bc8074 · Cited by 7
Scott-Herridge, J., Seifer, C. M., Steigerwald, R., Drobot, G., & McIntyre, W. F. (2016) · Acute Cardiac Care · doi:10.1080/17482941.2017.1406954 · Cited by 6
“Despite strong clinical evidence of benefit, OAC use remains limited by non-prescription (<50%) (6,7), non-adherence (6) and sub-therapeutic drug levels (8,9), resulting in both high social and medical costs secondary to stroke (9), which are often more severe than strokes of other etiology (10).”
BackgroundUpdate on anti-coagulation in atrial fibrillation
Kreuzer, J. (2011) · QJM · doi:10.1093/qjmed/hcr107 · Cited by 6
Goralnick, E., & Bontempo, L. J. (2015) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2015.04.008 · Cited by 6
Physician Attitudes Concerning Anticoagulation Services in the Long-Term Care Setting
Harrold, L. R., Gurwitz, J. H., Tate, J. P., Becker, R. C., Stuart, T. L., Elwell, A., & Radford, M. J. (2002) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1022018422237 · Cited by 6
“Most recently, Matchar and colleagues performed a multi-site randomized trial examining the use of an anticoagulation service as compared to usual care in six large managed care organizations in the United States [11].”
BackgroundSafe and Effective Anticoagulation in the Outpatient Setting: A Systematic Review of the Evidence
He, B., Taylor, B. C., Krause, A., Reddy, P., Greer, N. L., MacDonald, R. H., Rutks, I. R., & Tj, W. (2011) · Cited by 6
Kow, C. S., Chen, F., Leong, S. K. J., Tham, K. Y., Yeoh, L., Chew, Z. M., Peh, W. J., & Thiruchelvam, K. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2523920 · Cited by 5
Jain, R., Fu, A.-C., Lim, J. T., Wang, C., Elder, J., Sander, S. D., & Tan, H. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.1.73 · Cited by 5
Do specialty anticoagulation clinics really outperform primary care at INR management?
Garrison, S., & Allan, G. M. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1113-2 · Cited by 5
“Another compared primary care management to that of an anticoagulation service [4].”
BackgroundPinto, S. S., Teixeira, A., Henriques, T. S., Monteiro, H. J., & Martins, C. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-040404 · Cited by 4
Clinical service organisation for adults with atrial fibrillation
Ferguson, C., Shaikh, F., Allida, S. M., Hendriks, J., Gallagher, C., Bajorek, B. V., Donkor, A., & Inglis, S. C. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013408.pub2 · Cited by 3
Metadata
- Authors
- Matchar, D. B., Samsa, G. P., Cohen, S. J., Oddone, E. Z., & Jurgelski, A. E.
- Affiliations
- Duke University (US)
- University of Arizona (US)
- Corresponding author
- Matchar, David B
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 113
- Issue
- 1
- Pages
- 42-51
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2063025825
- Cited by
- 141
- References
- 48
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 7 · 2016: 4 · 2015: 7 · 2014: 10 · 2013: 7 · 2012: 13
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- atrial fibrillation, anticoagulation management, warfarin, INR control, managed care organizations, anticoagulation service, stroke prevention, non-valvular atrial fibrillation, older adults, quality of care, implementation feasibility, time in therapeutic range, usual care comparison
- MeSH terms
- Aged, Anticoagulants, Atrial Fibrillation, Female, Health Maintenance Organizations, Humans, Male, Managed Care Programs, Prothrombin Time, Quality of Health Care, Risk Factors, United States, Warfarin, International Normalized Ratio, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
